Jayachandran, Muthuvel http://orcid.org/0000-0002-3007-0769
Yuzhakov, Stanislav V.
Kumar, Sanjay
Larson, Nicholas B.
Enders, Felicity T.
Milliner, Dawn S.
Rule, Andrew D.
Lieske, John C.
Funding for this research was provided by:
National Institutes of Health (U54DK083908, U54 DK100227, R25-DK101405)
Oxalosis and Hyperoxaluria Foundation
Mayo Foundation for Medical Education and Research
Article History
Received: 24 June 2020
Accepted: 3 November 2020
First Online: 11 November 2020
Change Date: 18 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13023-020-01671-7
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board at Mayo Clinic, Rochester, MN, USA. Primary hyperoxaluria type 1 patients were enrolled in the Mayo Clinic Rare Kidney Stone Consortium (RKSC) Primary Hyperoxaluria Registry and informed consent for participation in RKSC biobank.
: This manuscript did not show images of individual person data and therefore “not applicable”.
: The authors declare that they have no competing interests.